Fireside Chats, a new virtual series presented by Advarra, launches this month, bringing the research community together to discuss challenges and potential solutions.
In a recent webinar, Advarra IRB and research compliance experts discussed key areas to consider when ramping up research in the COVID-19 pandemic’s “new normal.”
Q&A: Gene Therapy Research in the Age of COVID-19: Study Startup for Infectious Disease, Oncology, and Rare Disease Research
In Advarra’s inaugural virtual symposium, experts from industry and academia met to discuss the unique challenges gene therapy research poses for research sites, sponsors, CROs, and study participants.
The site-sponsor relationship is a multi-faceted one. The need for communication and understanding between the two is prevalent now more than ever.
On June 3, members of the research community gathered virtually to discuss updates on hot topics and emerging issues in gene therapy.
The global pandemic has changed the way we think about research. Sponsors should consider how the “new normal” will impact sites and current studies as they plan to re-start research.
Biosafety has surged to the spotlight due to the current COVID-19 global pandemic, motivating sites to conduct a risk assessment and develop a risk mitigation plan.